false and misleading representations that the article was an adequate and effective treatment in controlling appetite, and causing one to lose weight immediately without tough diets; and, in addition, the display cartons contained statements that the article had just been released by the Federal Government for over the counter sale and that the article contained no harmful drugs, which statements were false and misleading since it contained the drug phenylpropanolamine which is not a harmless drug; certain precautions must be observed in its use; and such drug had not been "just released" but has been available for sale without prescription for a number of years under labeling which contains appropriate restrictions on the dosage and with caution against use by individuals with high blood pressure, heart disease, diabetes, and thyroid disease, except as directed by a physician.

DISPOSITION: 11–10–59. Default—destruction.

6011. Alfex alfalfa tablets. (F.D.C. No. 43151. S. No. 54–869 P.)

QUANTITY: 7 drums, each containing between 22,000 and 32,000 tablets and several hundred 30-tablet, 100-tablet, and 200-tablet btls. at Philadelphia, Pa., in possession of Shane Laboratories, Inc.

SHIPPED: 3–23–59, from North Kansas City, Mo.

LABEL IN PART: (Drum) "Alfex Tablets Concentration 29,000 * * * Caution: For Repackaging Use Only"; (btl.) "Alfex Hi-Potency Alfalfa Extract 400 Mg. In Each Tablet * * * Distributed by Shane Laboratories, Philadelphia * * * Pa."

ACCOMPANYING LABELING: Leaflets entitled "A Message of Hope for Arthritic Sufferers"; a form letter headed "Dear Pharmacist"; a window display banner reading: "Pains? Stiffness? Why Suffer? Arthritis For Relief Take Alfex Tablets"; and a newspaper advertisement used as a counter display headed "Arthritis Sufferers At Last! Amazing Fast Relief from Arthritis-Sciatica-Rheumatism-Bursitis Alfex."

RESULTS OF INVESTIGATION: The tablets in the bottle were repackaged by Shane Laboratories, Inc., from bulk drums which were shipped as described above.

LIBELED: 5–21–59, E. Dist. Pa.

CHARGE: 502(a)—while held for sale, the labeling contained false and misleading representations that the article was adequate and effective in the treatment of arthritis, rheumatism, sciatica, and bursitis.

DISPOSITION: 8–19–59. Consent—claimed by Shane Laboratories, Inc., and reworked and relabeled.

6012. Kank-A solution. (F.D.C. No. 43277. S. No. 63–629 P.)

QUANTITY: 36 ctns., each containing one display card of 14 vials each, and 17 ctns., each containing one display card of 28 vials each, at Boston, Mass.

SHIPPED: 5–25–59 and 6–2–59, from Plymouth, N.H., by John Arthur Geyer Co.

LABEL IN PART: (Ctn.) "One Card Kank-A * * * Mr. Druggist: Recommend Kank-A," (display card) "Use Kank-A," and (vial) "Kank-A * * * Contents: Myrrh, Benzoin, S.D., Alcohol."

LIBELED: 6–23–59, Dist. Mass.; amended libel 6–24–59.

CHARGE: 502(a)—when shipped, the labeling contained false and misleading representations that the article was an adequate and effective treatment for canker sores and denture sores; 502(c)—the information required by the Act to appear on the labeling, namely, the common or usual names of the active